Cargando…
Doxycycline in the Coronavirus Disease 2019 Therapy
Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce the need for hospitalisation. In the article, the patients with mild to moderate coronavirus dise...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464303/ https://www.ncbi.nlm.nih.gov/pubmed/34584416 http://dx.doi.org/10.2147/TCRM.S314923 |
_version_ | 1784572601873465344 |
---|---|
author | Dorobisz, Karolina Dorobisz, Tadeusz Janczak, Dariusz Zatoński, Tomasz |
author_facet | Dorobisz, Karolina Dorobisz, Tadeusz Janczak, Dariusz Zatoński, Tomasz |
author_sort | Dorobisz, Karolina |
collection | PubMed |
description | Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce the need for hospitalisation. In the article, the patients with mild to moderate coronavirus disease 2019 (COVID-19) treated with doxycycline with significant improvement have been discussed. Doxycycline is a known antibiotic, but also an anti-inflammatory and immunomodulatory drug, so it seems to be ideal for the treatment of COVID-19. Doxycycline, as an easily available and low-cost medication, should be considered as a COVID-19 therapy in all patients in the first days of the symptoms of a SARS-CoV-2 infection. Due to its immunomodulatory, anti-inflammatory, cardioprotective and antiviral effects, it seems to be an ideal drug for patients with mild, moderate and severe disease. A large multicentre study is needed to evaluate the effects of this medication. |
format | Online Article Text |
id | pubmed-8464303 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84643032021-09-27 Doxycycline in the Coronavirus Disease 2019 Therapy Dorobisz, Karolina Dorobisz, Tadeusz Janczak, Dariusz Zatoński, Tomasz Ther Clin Risk Manag Case Series Acute respiratory syndrome, associated with coronavirus 2 (SARS-CoV-2), is the most important medical and epidemic problem of today. The biggest challenge is to find an effective treatment and to reduce the need for hospitalisation. In the article, the patients with mild to moderate coronavirus disease 2019 (COVID-19) treated with doxycycline with significant improvement have been discussed. Doxycycline is a known antibiotic, but also an anti-inflammatory and immunomodulatory drug, so it seems to be ideal for the treatment of COVID-19. Doxycycline, as an easily available and low-cost medication, should be considered as a COVID-19 therapy in all patients in the first days of the symptoms of a SARS-CoV-2 infection. Due to its immunomodulatory, anti-inflammatory, cardioprotective and antiviral effects, it seems to be an ideal drug for patients with mild, moderate and severe disease. A large multicentre study is needed to evaluate the effects of this medication. Dove 2021-09-21 /pmc/articles/PMC8464303/ /pubmed/34584416 http://dx.doi.org/10.2147/TCRM.S314923 Text en © 2021 Dorobisz et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Case Series Dorobisz, Karolina Dorobisz, Tadeusz Janczak, Dariusz Zatoński, Tomasz Doxycycline in the Coronavirus Disease 2019 Therapy |
title | Doxycycline in the Coronavirus Disease 2019 Therapy |
title_full | Doxycycline in the Coronavirus Disease 2019 Therapy |
title_fullStr | Doxycycline in the Coronavirus Disease 2019 Therapy |
title_full_unstemmed | Doxycycline in the Coronavirus Disease 2019 Therapy |
title_short | Doxycycline in the Coronavirus Disease 2019 Therapy |
title_sort | doxycycline in the coronavirus disease 2019 therapy |
topic | Case Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464303/ https://www.ncbi.nlm.nih.gov/pubmed/34584416 http://dx.doi.org/10.2147/TCRM.S314923 |
work_keys_str_mv | AT dorobiszkarolina doxycyclineinthecoronavirusdisease2019therapy AT dorobisztadeusz doxycyclineinthecoronavirusdisease2019therapy AT janczakdariusz doxycyclineinthecoronavirusdisease2019therapy AT zatonskitomasz doxycyclineinthecoronavirusdisease2019therapy |